Piezo1 facilitates optimal T cell activation during tumor challenge

IF 7.2 2区医学

Oncoimmunology Pub Date : 2023-11-22 DOI:10.1080/2162402x.2023.2281179

muta abiff, Mohammad Alshebremi, Melissa Bonner, Jay T. Myers, Byung-Gyu Kim, Suzanne L. Tomchuck, Alicia Santin, Daniel Kingsley, Sung Hee Choi, Alex Y. Huang

引用次数: 0

Abstract

Functional effector T cells in the tumor microenvironment (TME) are critical for successful anti-tumor responses. T cell anti-tumor function is dependent on their ability to differentiate from a na...

查看原文本刊更多论文

Piezo1促进最佳的T细胞激活在肿瘤的挑战

肿瘤微环境中的功能效应T细胞(TME)对成功的抗肿瘤反应至关重要。T细胞的抗肿瘤功能依赖于它们与na细胞的分化能力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.